Gunderson Dettmer represented Carbon Biosciences on the deal.Carbon Biosciences, a developer of novel parvovirus-derived gene therapies, announced its emergence from stealth mode and the closing of a…
Carbon Biosciences’ $38 Million Series A Financing
